Epizyme Announces Clinical And Pre-Clinical Data To Be Featured In Oral And Poster Presentations At American Society Of Hematology (ASH) Annual Meeting

Epizyme, Inc.

, a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that clinical and pre-clinical data on its first-in-class histone methyltransferase (HMT) inhibitors will be highlighted in oral and poster presentations at the 56th annual meeting of the American Society of Hematology (ASH), to be held December 6-9 in San Francisco, Calif. “Epizyme continues its scientific and clinical leadership in the field of HMTs, and the next two months will be particularly important for us as we share clinical data from our two lead programs, with a late-breaking oral presentation of our EPZ-6438 data at the EORTC-NCI-AACR Symposium in November and the oral presentation of the EPZ-5676 data at ASH in December,” said Robert Gould, Ph.D., President and Chief Executive Officer, Epizyme. “We are also pleased to be able to share at ASH pre-clinical data on our first-in-class PRMT5 inhibitor, a promising development candidate from the Epizyme pipeline, as well as pharmacokinetic modeling for the EPZ-5676 pediatric Phase 1 study.” The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia Presenter: Eytan Stein, M.D., Memorial Sloan Kettering Cancer Center, New York Session title: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Drugs II Presentation time: Monday, December 8, 2014 at 11:00 a.m. PT Abstract Number: 387 Identification of a First-in-Class PRMT5 Inhibitor with Potent In Vitro and In Vivo Activity in Pre-clinical Models of Mantle Cell Lymphoma Presenter: Elayne Penebre, Ph.D., Senior Scientist, Epizyme Session title: Chemical Biology and Experimental Therapeutics: Identification and Preclinical Evaluation of Novel Genetic and Epigenetic Targeted Therapies Presentation time: Monday, December 8, 2014 at 11:45 a.m. PT Abstract Number: 438 Pediatric Dose Determinations for the Phase 1 Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling Presenter: Nigel Waters, Ph.D., Director, Drug Metabolism and Pharmacokinetics, Epizyme Session title: Molecular Pharmacology and Drug Resistance in Myeloid Diseases Presentation time: Monday, December 8, 2014, 6:00 to 8:00 p.m. PT Abstract Number: 3619